Fulgent Genetics CSO sells 1,673 shares for taxes

Fulgent Genetics’ Chief Scientific Officer sold shares to cover taxes from RSU vesting and now directly holds 986,117 shares.

Rhea-AI Filing Summary

Fulgent Genetics, Inc. (FLGT) reported that Chief Scientific Officer Hanlin Gao sold 1,673 shares of common stock on September 2, 2026 at a weighted-average price of $19.66 per share. According to the disclosure, the sale was made to satisfy tax withholding obligations arising from the vesting of restricted stock units. Following this sale, Gao directly holds 986,117 shares of Fulgent Genetics common stock.

Insider Trade Summary

Net Seller: 1,673 shares

Net Sell 1 txn

Insider Gao Hanlin

Role Chief Scientific Officer

Sold 1,673 shs ($33K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	1,673	$19.6564	$33K

Holdings After Transaction: Common Stock — 986,117 shares (Direct)

Footnotes (2)

1. F1. The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025.
2. F2. The shares were sold in multiple transactions at prices ranging from $19.60 to $19.74, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

Key Figures

Shares sold: 1,673 shares Weighted-average sale price: $19.66 per share Sale price range: $19.60–$19.74 per share +2 more

5 metrics

Shares sold 1,673 shares Common stock sale by Chief Scientific Officer on September 2, 2026

Weighted-average sale price $19.66 per share Average price across multiple sale transactions on September 2, 2026

Sale price range $19.60–$19.74 per share Range of prices for multiple sale executions on September 2, 2026

Shares held after transaction 986,117 shares Direct holdings of Hanlin Gao following the sale

Transaction date September 2, 2026 Date of the reported insider sale

Key Terms

restricted stock units, tax withholding obligations, weighted-average sale price

3 terms

restricted stock units financial

"tax withholding obligations that arose upon the vesting of certain restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"shares were sold by the reporting person to satisfy the tax withholding obligations"

weighted-average sale price financial

"reported price reflects the weighted-average sale price"

FAQ

What insider transaction did FLGT disclose for Hanlin Gao?

Fulgent Genetics disclosed that Chief Scientific Officer Hanlin Gao sold 1,673 shares of common stock on September 2, 2026 at a weighted-average price of $19.66 per share to satisfy tax withholding obligations from vested restricted stock units.

How many FLGT shares does Hanlin Gao hold after this Form 4 transaction?

After the reported sale, Chief Scientific Officer Hanlin Gao directly holds 986,117 shares of Fulgent Genetics common stock, as stated in the filing.

Why did the FLGT insider sell 1,673 shares?

The filing states the 1,673 shares were sold to satisfy tax withholding obligations that arose upon the vesting of certain restricted stock units previously granted to Chief Scientific Officer Hanlin Gao.

At what price range were Hanlin Gao’s FLGT shares sold?

The shares were sold in multiple transactions at prices ranging from $19.60 to $19.74 per share. The reported $19.66 figure is the weighted-average sale price across those transactions.

Was the FLGT insider sale made under a Rule 10b5-1 trading plan?

The Form 4 indicates no Rule 10b5-1 trading plan for this transaction, and the footnotes describe the sales as made to cover tax withholding on vested restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 07:48 PM Accepted by SEC EDGAR 09/03/2026 - 07:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gao Hanlin

(Last) (First) (Middle)

C/O FULGENT GENETICS, INC.

4399 SANTA ANITA AVENUE

(Street)

EL MONTE CALIFORNIA 91731

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2026		S		1,673(1)	D	$19.6564(2)	986,117	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025.

2. The shares were sold in multiple transactions at prices ranging from $19.60 to $19.74, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

	/s/ Paul Kim as Attorney-in-Fact	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)